620533-90-6

Basic information

• Product Name: Benzene, 1-(azidomethyl)-3-(trifluoromethyl)-
• CAS NO: 620533-90-6
• Molecular Formula: C8H6F3N3
• Molecular Weight: 201.151
• Mol File: 620533-90-6.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(azidomethyl)-3-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(azidomethyl)-3-(trifluoromethyl)-(620533-90-6)
• EPA Substance Registry System: Benzene, 1-(azidomethyl)-3-(trifluoromethyl)-(620533-90-6)

Safety Data

• Hazardous Substances Data: 620533-90-6(Hazardous Substances Data)

Upstream product

• 402-23-3 1-bromomethyl-3-trifluoromethylbenzene 
• 705-29-3 3-Trifluoromethylbenzyl chloride 

Downstream Products

• 1280497-56-4 2-(1-(3-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-5-yl)-pyridine 
• 785822-34-6 N-(3-(trifluoromethyl)benzyl)benzamide 
• 63777-75-3 1-(3-(trifluoromethyl)benzyl)-1H-1,2,3-triazole 
• 1198769-40-2 1-(3-(trifluoromethyl)benzyl)-4-phenyl-1H-1,2,3-triazole 
• 1198769-39-9 5-iodo-4-phenyl-1-(3-(trifluoromethyl)benzyl)-1H-1,2,3-triazole 
• 1399679-77-6 4-[(phenylselanyl)methyl]-1-[3-(trifluoromethyl)benzyl]-1H-1,2,3-triazole 
• 1333142-35-0 C₁₆H₂₀F₃N₅O₂S 

Relevant articles and documents

Dipolar HCP materials as alternatives to DMF solvent for azide-based synthesis

Hypercrosslinked polymers HCP-DMF and HCP-DMF-SO3H containing abundant and flexible DMF moieties were designed and synthesized. Benefitting from the solvation microenvironment provided by the pseudo-DMF moities, the polar HCPs manifested outstanding performances in the conversions of NaN3 to benzylic azides and 1,2,3-triazoles in EtOH (95%), respectively, avoiding the use of risky DMF and improving the separation processes of the products.

NOVEL DIBENZOOXAPHOSPHININE OXIDE DERIVATIVE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE DISEASE COMPRISING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel dibenzooxininin oxide derivative compound having various nitrogen-containing substituents introduced at 6-position of a dibenzooxaphosphorin oxide mononuclear, and to the use thereof. The present invention relates to a pharmaceutical composition for preventing or treating degenerative diseases and a health supplement food composition for preventing or treating degenerative diseases, comprising the dibenzooxaphosphorin oxide derivative compound of the present invention.

Discovery and Characterization of 1 H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy

The prostanoid EP4 receptor is one of the key receptors associated with inflammatory mediator PGE2-elicited immunosuppression in the tumor microenvironment. Blockade of EP4 signaling to enhance immunity-mediated tumor elimination has recently emerged as a promising strategy for cancer immunotherapy. In our efforts to discover novel subtype-selective EP4 antagonists, we designed and synthesized a class of 1H-1,2,3-triazole-based ligands that display low nanomolar antagonism activity toward the human EP4 receptor and excellent subtype selectivity. The most promising compound 59 exhibits single-digit nanomolar potency in the EP4 calcium flux and cAMP-response element reporter assays and effectively suppresses the expression of multiple immunosuppression-related genes in macrophage cells. On the basis of its favorable ADMET properties, compound 59 was chosen for further in vivo biological evaluation. Oral administration of compound 59 significantly inhibited tumor growth in the mouse CT26 colon carcinoma model accompanied by enhanced infiltration of cytotoxic T lymphocytes in the tumor tissue.